<DOC>
	<DOCNO>NCT00231764</DOCNO>
	<brief_summary>To determine renal function , express glomerular filtration rate 12 month , renal transplant recipient receive mycophenolate mofetil , daclizumab , corticosteroid mainstay immunosuppression combination low-dose cyclosporine , tacrolimus , sirolimus , compare renal transplant recipient receive standard immunosuppression mycophenolate mofetil , normal dose cyclosporine corticosteroid .</brief_summary>
	<brief_title>MMF , Daclizumab Corticosteroids Mainstay Immunosuppression Renal Transplant Patients</brief_title>
	<detailed_description>The purpose SYMPHONY study compare four different immunosuppressive regimen . They give one year . The following four combination test four group patient : - Group A : Cyclosporine normal dosage , mycophenolate mofetil ( MMF ) corticosteroids - Group B : Daclizumab first two month transplantation , cyclosporine low dosage compare group A , mycophenolate mofetil ( MMF ) corticosteroids - Group C : Daclizumab first two month transplantation , tacrolimus low dosage , mycophenolate mofetil ( MMF ) corticosteroids - Group D : Daclizumab first two month transplantation , sirolimus low dosage , mycophenolate mofetil ( MMF ) corticosteroid . All drug four immunosuppressive regime approve Health Authorities participate country use kidney transplantation . The regimen administer patient Group A represent standard treatment , currently give success many transplant patient number country world . The treatment Groups B , C D experimental sense either dos administer low one use and/or combination drug experimental . Nevertheless , result scientific study indicate effective alternative might advantage compare standard immunosuppressive regimen , particular far safety ( side effect , long-term toxicity ) concern . However , previous clinical experience , yet clear regimen offer advantage patient . To find , SYMPHONY four regimen administer four group patient ( A-D ) result different group compare .</detailed_description>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Male female patient 18 75 year Recipients singleorgan renal primary allograft second renal transplant ( provide previous graft lose acute rejection within first year ) living cadaver donor Patients provide write informed consent . PRA &gt; 20 % within 6 month prior enrollment Cold ischemia time &gt; 30 hour Previous treatment daclizumab History malignancy ( except localize skin cancer ) Active peptic ulcer disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Renal transplantation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Daclizumab</keyword>
	<keyword>GFR</keyword>
</DOC>